Liver diseases, both acute and chronic, continue to pose significant clinical challenges due to high morbidity and mortality rates.
Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares | Psychedelic Invest
VANCOUVER, BC, June 12, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today
June 13, 2024